Letter by Smolderen and Pelle regarding article, "Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial".
Smolderen
Kim G
KG
Pelle
Aline J
AJ
D001552:Benzazepines / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003863:Depression / Q000453:epidemiology*; D006801:Humans; D018722:Nicotinic Agonists / Q000627:therapeutic use; D018579:Patient Selection; D011810:Quinoxalines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D016540:Smoking Cessation / Q000379:methods*; D000068580:Varenicline
D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline